Redeye states that Q1 came in lower than expected due to less revenues from the Saudi deal, and a larger negative impact on US revenues due to lock downs. We lower our 2021 estimates but raise estimates for 2022. We maintain our valuation.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/